达普司他的用药指南

Daprostat is a new hypoxia-inducible factor prolyl hydroxylase inhibitor, mainly used to treat anemia related to chronic kidney disease. The drug improves anemia symptoms by simulating a hypoxic environment and promoting the production of endogenous erythropoietin. Daprostat is not yet on the market in China, nor is it covered by medical insurance, but generic drugs are available on the market.

Daplostat Medication Guide

The medication of daplostat needs to be individually adjusted according to the patient's specific conditions, including dosage, monitoring and precautions, and must be administered strictly under the guidance of a doctor.

Usage and Dosage

The recommended starting dose of daprostat needs to be determined based on the patient’s hemoglobin level. For adult patients not receiving ESA therapy, the starting dose is usually 1 mg to 8 mg once daily. The medicine can be taken with food or alone, but the tablet must be swallowed whole and not cut or chewed. If you miss a dose, you should take it as soon as possible on the same day. If it is close to the time of the next dose, skip it to avoid a double dose.

Treatment monitoring

After the start of treatment, hemoglobin levels need to be monitored regularly, once every 2 weeks for the first 2 weeks, and once every 4 weeks thereafter. Adjust the dose according to changes in hemoglobin, no more frequently than every 4 weeks. At the same time, iron stores and liver function need to be assessed, and iron supplements should be supplemented if necessary.

Dose adjustment

Patients with moderate hepatic impairment or taking CYP2C8 inhibitors need to reduce the starting dose. Except for patients whose starting dose is already 1 mg, patients with moderate hepatic impairment (Child-Pugh Class B) will have the starting dose of daprostat reduced by half. Patients with severe hepatic impairment are contraindicated. If abnormal hemoglobin fluctuations occur during treatment, the dose should be adjusted promptly and monitored closely.

Side effects of daprostat

Daprostat may cause a variety of adverse reactions during treatment, and patients need to understand and be alert to these potential risks.

Common adverse reactions

Hypertension, hyperthrombotic events and abdominal pain are the most common adverse reactions of daprostat. Patients need to monitor their blood pressure regularly and adjust antihypertensive drugs if necessary.

Serious Risks

Daprostat may increase the risk of arterial and venous thrombotic events, including myocardial infarction, stroke, and vascular access thrombosis. Patients with relevant medical history should avoid use. In addition, the risk of gastrointestinal bleeding and hospitalization for heart failure are also of concern.

Precautions

Patients should avoid smoking and drinking during medication to reduce the risk of gastrointestinal erosion. If you have chest pain, difficulty breathing or gastrointestinal bleeding, seek medical attention immediately.

Daplostat’s use in special populations

Special attention should be paid to dose adjustment and safety issues when using daplostat in different populations.

Pregnant and lactating women

There are limited safety data on the use of daplostat in pregnant women, so it should be used with caution after weighing the pros and cons. Lactating women should suspend breastfeeding while taking the drug to avoid potential effects on the baby.

Children and elderly patients

The safety and effectiveness of daprostat in children have not been established and its use is not recommended. Elderly patients do not need special dosage adjustments, but adverse reactions need to be closely monitored.

Patients with liver impairment

Patients with mild liver impairment do not need to adjust the dose, and patients with moderate liver impairment need to reduce the starting dose by half. Daprostat is contraindicated in patients with severe hepatic impairment to avoid the risk of drug accumulation and toxicity.

Patients must strictly follow the doctor's instructions when using it, pay attention to dosage adjustment and adverse reaction monitoring.